Was Retatrutide Studied in People Who Are Not Overweight?
What BMI ranges the retatrutide trials enrolled, from the phase 1 healthy-participant studies to the phase 3 records, and where published data is absent.
Research use only. This page provides scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research. Nothing on this page is a protocol, a recommendation, or medical advice.
TL;DR: lower BMI eligibility is documented; dedicated weight outcomes are absent
The question people actually type: was retatrutide studied in people who are not overweight?
What the published data say: early healthy-participant studies allowed BMI ranges extending below the overweight range. The associated publication does not report a below-overweight subgroup. [NCT03841630; NCT06003465; PMID 35985340]
What the documented search did not identify: as of 2026-09-12, no published study reports body-weight outcomes for retatrutide in a population selected for a BMI below the overweight range. [PubMed search, 2026-09-12, described below]
What research communities report: In the Reddit corpus we track, 259 question posts in 12 months and 6 in the 4 to 12 September 2026 window matched this question pattern. These are reports, not evidence of how frequently a clinical outcome occurs.
What BMI did the main retatrutide trials require?
The phase 2 obesity trial required a BMI of 30 or higher, or 27 to under 30 with a weight-related condition. Its 338 adults were followed for 48 weeks; its registry capped BMI at 50 and specified ages 18 to 75. These were enrollment boundaries, not findings about people outside those boundaries. [PMID 37366315; NCT04881760]
TRIUMPH-1 used the same lower eligibility thresholds and also required a history of an unsuccessful dietary weight-loss effort. TRIUMPH-2 required participants with type 2 diabetes and BMI of 27.0 or higher. The other records show why a single BMI threshold cannot describe the whole program. [NCT05929066; NCT05929079; NCT05882045; NCT05931367]
- BMI eligibility
- 30 to 50, or 27 to under 30 with a weight-related condition
- Comparator: phase 2 eligibility
- Reference criteria
- BMI eligibility
- 27.0 or higher
- Comparator: phase 2 eligibility
- Matches the conditional lower floor
- BMI eligibility
- 35.0 or higher
- Comparator: phase 2 eligibility
- Higher lower limit
- BMI eligibility
- 27 or higher
- Comparator: phase 2 eligibility
- Matches the conditional lower floor
This table compares enrollment criteria across studies. It does not compare outcomes or imply that the enrolled populations were interchangeable. The accompanying condition remains part of each trial's eligibility definition.
Did any trial allow BMI below the overweight range?
Yes, the healthy-participant registry windows extended that low: BMI 19 to 40 in NCT03841630 and 18.5 to 32.0 in NCT06003465. The records list 45 and 57 participants, respectively. A permitted range establishes who could qualify; it does not disclose how many enrolled participants occupied its lower end. [NCT03841630; NCT06003465]
Among the phase 3 records, TRANSCEND-T2D-1 has the lowest BMI floor, 23.0, and lists 537 enrolled participants with type 2 diabetes. That is a different population from the healthy-participant studies. Its eligibility cannot be rewritten as a trial restricted to people who are not overweight. [NCT06354660]
The answer therefore depends on the meaning of “studied.” Lower BMI eligibility appears in human research records. Published weight outcomes specifically for a population selected below the overweight range are a separate question, addressed below.
What did the healthy-participant studies measure?
The early studies focused on safety and pharmacokinetics: NCT03841630 listed drug-related serious adverse events as its primary endpoint, while the device comparison study NCT06003465 measured pharmacokinetics only. Neither endpoint description establishes weight outcomes for a lower-BMI subgroup. [NCT03841630; NCT06003465]
The publication associated with the earlier healthy-participant study reports a body-weight reduction persisting to day 43 after a single dose, but it does not report a below-overweight subgroup. The observation belongs to that study's reported population; it cannot supply a separate estimate for participants at the lower end of its eligible BMI window. [PMID 35985340; NCT03841630]
“Healthy participants” is consequently an enrollment description, not a synonym for a study selected entirely below the overweight range. The broad BMI windows and the endpoints need to be read together. [NCT03841630; NCT06003465]
Is there published weight data for a population below the overweight range?
No published study reports those population-specific body-weight outcomes as of 2026-09-12. The documented PubMed search combined retatrutide or LY3437943 with terms for normal weight and related descriptions, returned 13 records, and checked every title. None enrolled a population selected below the overweight range. [PubMed search, 2026-09-12]
A ClinicalTrials.gov search for retatrutide plus “normal weight” also returned no study. That wording search is narrower than a review of numeric BMI criteria: it does not erase the healthy-participant records described above. [ClinicalTrials.gov search, 2026-09-12]
TRANSCEND-T2D-1 lists change in HbA1c as its primary outcome and percentage change in body weight as a secondary outcome at week 40. It has no posted results. A registered outcome is a planned measurement, so this record supplies eligibility and endpoint information, not a published weight result at BMI 23.0. [NCT06354660]
Does an approved label define a retatrutide population?
No. Retatrutide has no approved label and no marketing authorization in the EU or the US, so there is no approved label population of any body weight. The FDA and EMA checks dated 2026-09-12 found no approved retatrutide application or medicines-table entry. [FDA Drugs@FDA; EMA medicines output table]
The FDA directory entries identified in that check were bulk-ingredient registrations. They do not establish an approved population. This answer rests on retatrutide records, without borrowing eligibility or label conclusions from another compound. [FDA Drugs@FDA and NDC directory, 2026-09-12]
PeptidesDirect does not sell tirzepatide.
Whether an individual at a given body weight should use an unapproved investigational compound is a medical question this page cannot answer.
Products mentioned
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.
Research use only. Retatrutide is supplied strictly for in-vitro research. Nothing on this page is a protocol, a recommendation, or medical advice.
Sources
- Jastreboff AM, et al. 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med 389(6):514-526. PMID 37366315.
- Coskun T, et al. 2022. LY3437943, a triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 34(9):1234-1247.e9. PMID 35985340.
- ClinicalTrials.gov: NCT04881760, NCT05929066, NCT05929079, NCT05882045, NCT05931367, NCT06354660, NCT03841630, NCT06003465. Eligibility and outcomes; documented retatrutide AND “normal weight” search, 2026-09-12.
- PubMed. 2026-09-12. Documented retatrutide / LY3437943 and normal-weight-related search, 13 records; all titles checked.
- openFDA Drugs@FDA and NDC directory, 2026-09-12: https://api.fda.gov/drug/drugsfda.json, https://api.fda.gov/drug/ndc.json
- EMA medicines output table, downloaded 2026-09-12: https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.